Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
99 participants
INTERVENTIONAL
2012-03-31
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma
NCT05626127
The Value of Diffusion-weighted Imaging in Evaluating the Early Efficacy of Liver Metastasis in Colorectal Cancer
NCT03088163
Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body
NCT02201797
Evaluation of PET/MRI in Patients With Pancreatic Adenocarcinoma
NCT02028377
Use of DwI-MR to Predict Chemotherapy Response of Liver Metastases and Hepatocarcinoma
NCT01411579
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MRCP and DWI using 3T MRI
MRCP and DWI using Magnetic resonance imaging（GE Signa,3.0 T )
3T MRI
diffusion weighted imaging(DWI) of biliary tract with GE Signa 3-tesla device
MRCP only using 3T MRI
MRCP only using Magnetic resonance imaging（GE Signa,3.0 T )
3T MRI
diffusion weighted imaging(DWI) of biliary tract with GE Signa 3-tesla device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
3T MRI
diffusion weighted imaging(DWI) of biliary tract with GE Signa 3-tesla device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Suspected Biliary Tract Neoplasm based on clinical symptoms(such as jaundice and thinness with unknown reasons)and CA-199 raises（\>37U/mL）
* No evidence of clinical symptoms or CA-199 increase by non-bile duct cancerous factors(hepatitis,cholangeitis,stones)
* Age ≥ 16
Exclusion Criteria
* Contraindication for MRI (such as pacemaker or inner ear implant)
* Claustrophobia
* Age \< 16
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Hospital of China Medical University
OTHER
China Medical University, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiaoping Yang
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaoping yang, MD
Role: PRINCIPAL_INVESTIGATOR
First Affiliated Hospital of China Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Room of 3.0TMR in the FAH of CMU
Shenyang, Liaoning, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XYang
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.